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Related Literature
PubMed was the primary search engine used to identify relevant articles, and publications were limited to the last fifteen years as there has been relatively less research done on INR reversal in patients with liver disease compared to INR reversal in patients being treated with warfarin. Various combinations of the following keywords were used: "INR reversal," "prothrombin complex concentrates," "recombinant factor vii," "fresh frozen plasma," "surgical intervention," "coagulopathy," and "liver disease." Most combinations included "liver disease" as articles that related to INR reversal in patients with liver disease were preferred over literature describing patients with warfarin-induced coagulopathy. Combinations included 3-4 of the aforementioned keywords, which usually returned 20-50 results depending on the combination used. Even with this strategy, most research on the topic pertained to the role of fresh-frozen plasma (FFP), prothrombin complex concentrates (PCCs) and recombinant factor VIIa (rFVIIa) specifically in the reversal of warfarin therapy. Very few articles directly address their use in lowering the INR of patients with nonmedication-induced coagulopathy (e.g., liver disease). Furthermore, articles describing the use of PCCs and rFVIIa in the reversal of supratherapeutic INR were scarce compared to the role of FFP. There is also limited research showing how FFP, PCCs and rFVIIa compare in terms of time to correction of INR and thus expedition of invasive procedures. Therefore, with these limitations in mind, articles were deemed relevant for use in this clinical context if they included INR reversal in patients with liver disease, and/or the use of PCCs and rFVIIa in patients with elevated INR regardless of etiology since these treatment modalities were already rarely described in the literature.
In a retrospective study done by Roitberg et al., neurosurgical patients who were administered rFVIIa had, on average, a greater reduction in INR (2.57 to 1.67) compared to patients administered FFP (2.17 to 1.85) . 1 This study also demonstrated that normalization of INR was quicker in patients who received rFVIIa versus FFP, with a mean difference of 40.66 hours. Furthermore, the number of patients with good functional outcome, described as having a Glasgow Outcome Scale score of 5, was greater among patients who received rFVIIa. These results suggest that the use of rFVIIa increases patient safety overall, in addition to a greater and quicker reduction in INR compared to FFP. This article describes coagulopathic patients who needed urgent INR reversal for neurosurgical intervention, closely resembling the patient described in the above clinical context. However, anticoagulation with warfarin was the cause of supratherapeutic INR in almost half of the patients who received rFVIIa, making it less comparable to the patient described in the clinical context. Furthermore, patients in the rFVIIa group were those who had failed initial coagulopathy reversal with FFP, and thus the effects of rFVIIa were not totally attributable to rFVIIa alone.
A systematic review by Chai-Adisaksopha et al. compared the role of PCCs versus FFP in the reduction of INR levels in patients requiring reversal of warfarin therapy. Their results show that the use of PCCs led to more rapid INR correction, a greater reduction in all-cause mortality, and less post-transfusion complications such as volume overload. 2 Though this article describes the role of PCCs in the reversal of supratherapeutic INR-a topic that is deficient in literature-it unfortunately includes patients with warfarininduced coagulopathy rather than liver disease. Their review also does not focus on INR reversal specifically for the purpose of urgent surgical intervention.
Ultimately, Kwon and MacLaren's article was selected for critical appraisal as it applies most to the scenario described in the clinical context above-a patient with coagulopathy secondary to liver disease who needed INR reversal for an invasive procedure.
Critical Appraisal
Kwon and MacLaren conducted a retrospective cohort study that included a total of forty-five patients aged 18-89 with liver impairment and a baseline INR of 1.5 or higher who were admitted to the intensive care unit (ICU) at the University of Colorado Hospital (UCH). Of these 45 patients, 15 patients each received FFP, PCCs, or rFVIIa prior to the procedure. This study design constitutes Level 2c evidence in accordance with the Oxford Centre for Evidence-based Medicine. Overall, this study demonstrated that PCCs and rFVIIa lowered INR more quickly and to a greater extent than FFP, thus expediting invasive procedures.3 Specifically, only 27% of the patients in the FFP group were able to achieve an INR of less than 1.5 in time for a procedure, compared to 80% in the PCCs group and 87% in the rFVIIa group. Furthermore, the average time to achieve an INR of 1.5 or less was 2.5, 2.1 and 1.8 hours for the FFP, PCCs and rFVIIa groups respectively. Various possible adverse events (e.g., minor or major bleeding, transfusion reactions, thromboembolic events) were also monitored, all of which were similar across all three groups with the exception of one complication-fluid overload. Hypervolemia was seen in 93% of patients in the FFP group versus 40% and 33% in the PCCs and rFVIIa groups respectively.
After thoroughly reviewing the article, there were a few noteworthy positive aspects with regards to the study design. Firstly, Kwon and MacLaren were very careful about which patients to include in the study. Patients were excluded if they were admitted for hemorrhage, if they were anticoagulated at therapeutic doses within 72 hours before the procedure, or if they possessed other etiologies of impaired or enhanced coagulation (e.g., disseminated intravascular coagulation, lupus). Patients were also excluded if their INR within the first 24 hours of admission were considered an outlier, i.e., excessively high or low. Both of these precautions established mean baseline INR values that were comparative across groups. In addition, baseline patient characteristics such as age, sex, ethnicity, and procedures to be performed were similar across all three groups, thus further mitigating the potential for confounding bias. It is also worth noting that an independent third-party data analyst generated the lists of screened patients, thereby addressing the possibility of selection bias.
There were also several limitations to consider in this study, beginning with the reporting of certain adverse events. Minor bleeding was defined by "a notation of bleeding associated with the procedure in the medical record" and major bleeding was defined as "minor bleeding and the need for a transfusion of packed red blood cells during or after the procedure." 3 As this is a retrospective study, the authors had to rely on documented decisions rather than something they could measure themselves. These decisions may not have been made identically for every patient, thus adding some variability and subjectivity to whether bleeding events were classified as minor or major-a form of measurement bias. Furthermore, the vast majority of procedures used in this study included common interventions such as central lines, tracheal intubation, arterial lines, paracentesis, endoscopy, chest tube insertion, and bronchoscopy, with relatively few patients undergoing biopsy in either of the three groups. It is possible that other procedures with higher risks of hemorrhage could have a different bleeding risk profile. Therefore, the scope of this study is, for the most part, limited to the common types of procedures mentioned above. Whether PCCs and rFVIIa reduce the overall bleeding risk for more invasive procedures such as brain biopsy still requires in-depth evaluation.
An additional limitation involves the arbitrary INR value of 1.5 as the threshold for bleeding prevention. This study showed that the application of this INR value to liver patients lacks validity since invasive procedures were still successfully and safely performed in the FFP group despite 73% of these patients not being able to achieve an INR less than 1.5. 3 The study's retrospective design and limited number of subjects also make it less possible to apply Kwon and MacLaren's findings in the clinical world. Despite these limitations, the study does still have value and surely warrants further investigation, possibly with a larger number of subjects and a prospective study design. Finally, it is possible to calculate the number needed to treat (NNT) with regards to one adverse eventhypervolemia. The NNT values for PCCs and rFVIIa (when comparing to FFP) were 1.89 and 1.67 respectively.
Clinical Application
The patient described in the clinical context closely resembles the patients used in Kwon and MacLaren's study. This was a patient with coagulopathy due to underlying liver disease who required urgent surgical intervention for diagnostic purposes. His baseline INR within 24 hours of admission was 1.76, a value that would not be considered an outlier by the appraised article's standards. However, additional concerns not covered by this study led to a final decision to use FFP-a total of 8 units-effectively lowering his INR from 1.69 to 1.40. A brain biopsy was finally performed and confirmed that the lesions were foci of metastases, likely secondary to a primary tumor of gastrointestinal origin that did not reveal itself on CT imaging.
Though Kwon and MacLaren's paper was discussed and their findings acknowledged by the team, a number of factors guided the clinical decision-making process with regards to using FFP over PCCs or rFVIIa for this patient. Firstly, a brain biopsy is perceived as having a higher risk of hemorrhage and more dangerous in a patient with coagulopathy than other common procedures. Since this specific type of procedure wasn't thoroughly investigated
